These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 11682253

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Associations between personality traits and CCK-4-induced panic attacks in healthy volunteers.
    Tõru I, Aluoja A, Võhma U, Raag M, Vasar V, Maron E, Shlik J.
    Psychiatry Res; 2010 Jul 30; 178(2):342-7. PubMed ID: 20471107
    [Abstract] [Full Text] [Related]

  • 23. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.
    Zwanzger P, Rupprecht R.
    J Psychiatry Neurosci; 2005 May 30; 30(3):167-75. PubMed ID: 15944741
    [Abstract] [Full Text] [Related]

  • 24. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings.
    Wiedemann K, Jahn H, Yassouridis A, Kellner M.
    Arch Gen Psychiatry; 2001 Apr 30; 58(4):371-7. PubMed ID: 11296098
    [Abstract] [Full Text] [Related]

  • 25. Benzodiazepines counteract rostral anterior cingulate cortex activation induced by cholecystokinin-tetrapeptide in humans.
    Leicht G, Mulert C, Eser D, Sämann PG, Ertl M, Laenger A, Karch S, Pogarell O, Meindl T, Czisch M, Rupprecht R.
    Biol Psychiatry; 2013 Feb 15; 73(4):337-44. PubMed ID: 23059050
    [Abstract] [Full Text] [Related]

  • 26. Effect of the GABA-transaminase inhibitor vigabatrin on exploratory behaviour in socially isolated rats.
    Sherif F, Oreland L.
    Behav Brain Res; 1995 Dec 14; 72(1-2):135-40. PubMed ID: 8788866
    [Abstract] [Full Text] [Related]

  • 27. Neurohormonal responses to cholecystokinin tetrapeptide: a comparison of younger and older healthy subjects.
    Flint AJ, Koszycki D, Bradwejn J, Vaccarino FJ.
    Psychoneuroendocrinology; 2000 Aug 14; 25(6):633-47. PubMed ID: 10840174
    [Abstract] [Full Text] [Related]

  • 28. Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder.
    Kellner M, Wiedemann K, Yassouridis A, Levengood R, Guo LS, Holsboer F, Yehuda R.
    Biol Psychiatry; 2000 Jan 15; 47(2):107-11. PubMed ID: 10664826
    [Abstract] [Full Text] [Related]

  • 29. Effect of oral ondansetron on total cholecystokinin plasma levels following CCK-4 panic challenge procedure in healthy men.
    Dépôt M, Merani S, Bradwejn J, Mukherjee J, Caillé J, Gutkowska J, Caillé G.
    J Psychiatry Neurosci; 1998 Nov 15; 23(5):298-304. PubMed ID: 9846035
    [Abstract] [Full Text] [Related]

  • 30. Cholecystokinin and panic disorder: past and future clinical research strategies.
    Bradwejn J, Koszycki D.
    Scand J Clin Lab Invest Suppl; 2001 Nov 15; 234():19-27. PubMed ID: 11713976
    [Abstract] [Full Text] [Related]

  • 31. Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers.
    McCann UD, Slate SO, Geraci M, Uhde TW.
    Anxiety; 2001 Nov 15; 1(6):258-67. PubMed ID: 9160584
    [Abstract] [Full Text] [Related]

  • 32. Inhibition of rabbit brain 4-aminobutyrate transaminase by some taurine analogues: a kinetic analysis.
    Ricci L, Frosini M, Gaggelli N, Valensin G, Machetti F, Sgaragli G, Valoti M.
    Biochem Pharmacol; 2006 May 14; 71(10):1510-9. PubMed ID: 16540097
    [Abstract] [Full Text] [Related]

  • 33. Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in health volunteers.
    Koszycki D, Bradwejn J, Bourin M.
    Eur Neuropsychopharmacol; 1991 May 14; 1(2):137-41. PubMed ID: 1821703
    [Abstract] [Full Text] [Related]

  • 34. Glyoxalase-I mRNA expression and CCK-4 induced panic attacks.
    Eser D, Uhr M, Leicht G, Asmus M, Länger A, Schüle C, Baghai TC, Mulert C, Rupprecht R.
    J Psychiatr Res; 2011 Jan 14; 45(1):60-3. PubMed ID: 20542521
    [Abstract] [Full Text] [Related]

  • 35. CCK-4-induced anxiety but not panic is associated with serum brain-derived neurotrophic factor in healthy subjects.
    Maron E, Tõru I, Mäemets K, Sepp S, Vasar V, Shlik J, Zharkovsky A.
    J Psychopharmacol; 2009 Jun 14; 23(4):460-4. PubMed ID: 18562429
    [Abstract] [Full Text] [Related]

  • 36. Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder.
    Katzman MA, Koszycki D, Bradwejn J.
    Depress Anxiety; 2004 Jun 14; 20(2):51-8. PubMed ID: 15390214
    [Abstract] [Full Text] [Related]

  • 37. Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder.
    Zwanzger P, Eser D, Nothdurfter C, Baghai TC, Möller HJ, Padberg F, Rupprecht R.
    Pharmacopsychiatry; 2009 Nov 14; 42(6):266-9. PubMed ID: 19924586
    [Abstract] [Full Text] [Related]

  • 38. The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers.
    Tõru I, Maron E, Raag M, Vasar V, Nutt DJ, Shlik J.
    Eur Neuropsychopharmacol; 2013 Jul 14; 23(7):645-52. PubMed ID: 22939006
    [Abstract] [Full Text] [Related]

  • 39. The ventilatory response to cholecystokinin tetrapeptide in healthy volunteers.
    Katzman MA, Duffin J, Shlik J, Bradwejn J.
    Neuropsychopharmacology; 2002 Jun 14; 26(6):824-31. PubMed ID: 12007753
    [Abstract] [Full Text] [Related]

  • 40. Association testing of panic disorder candidate genes using CCK-4 challenge in healthy volunteers.
    Maron E, Tõru I, Tasa G, Must A, Toover E, Lang A, Vasar V, Shlik J.
    Neurosci Lett; 2008 Dec 03; 446(2-3):88-92. PubMed ID: 18832011
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.